News Center

——

News Center

图片名称

Company News

Industry News

News Center

21

2026-04

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor induces targeted-protein degradation through lysosomal autophagy

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor induces targeted-protein degradation through lysosomal autophagy

07

2024-04

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models

07

2024-04

BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models

BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models

21

2023-11

BroadenBio Announces First Patient Enrollment in Phase I Study of HPK1 inhibitor BB3008

BroadenBio Announces First Patient Enrollment in Phase I Study of HPK1 inhibitor BB3008

30

2023-09

BroadenBio's BB3008 approved by CDE & FDA to enter clinic for advanced solid tumors

BroadenBio's BB3008 approved by CDE & FDA to enter clinic for advanced solid tumors

07

2023-09

BroadenBio's BB3008 cleared by FDA to enter clinic for advanced solid tumors

BroadenBio's BB3008 cleared by FDA to enter clinic for advanced solid tumors

< 1 2 3 4 >

address：

A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176

phone：

e-mail：

hr@broadenbio.com

Copyright ©2019 BroadenBio

Powered by www.300.cn

business license